Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
- 15 September 2011
- journal article
- research article
- Published by Elsevier BV in Journal of the Neurological Sciences
- Vol. 308 (1-2), 98-102
- https://doi.org/10.1016/j.jns.2011.05.043
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Natalizumab dosage suspension: Are we helping or hurting?Annals of Neurology, 2010
- Natalizumab drug holiday in multiple sclerosis: Poorly ToleratedAnnals of Neurology, 2010
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesThe Lancet Neurology, 2010
- Balancing risk and reward: The question of natalizumabAnnals of Neurology, 2009
- New cases of progressive multifocal leukoencephalopathy after treatment with natalizumabThe Lancet Neurology, 2009
- POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTSNeurology, 2008
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- A Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2003
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983